Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
前收盘价
US$27.42
−US$0.54 · -1.93%
盘中时间采用ET。市场数据可能有所延迟。
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
日内区间
当前US$27.42
52周区间
当前US$27.42
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
10
估值过高
情绪
59
多空交织
风险
34
中等风险
动量
70
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
日内区间
当前US$27.42
52周区间
当前US$27.42
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 150万 USD | 702万 USD | 688.3万 USD | 235.7万 USD | 465.1万 USD |
| 销货成本 | — | 1.64亿 USD | 1.18亿 USD | 8225.8万 USD | 5331.1万 USD |
| 毛利 | 150万 USD | −1.57亿 USD | −1.11亿 USD | −7990.1万 USD | −4866万 USD |
| 研究与开发 | 2.45亿 USD | 1.64亿 USD | 1.18亿 USD | 8225.8万 USD | 5681.1万 USD |
| 销售、一般及管理费用 | 4380万 USD | 3854.8万 USD | 3091.4万 USD | 2719.5万 USD | 2048.8万 USD |
| 营业费用 | 2.89亿 USD | 3854.8万 USD | 4341.4万 USD | 3533.3万 USD | 2258.3万 USD |
| 利息收入 | 2861万 USD | 3721.5万 USD | 1311.3万 USD | 290.9万 USD | 50.5万 USD |
| 折旧和摊销 | 338万 USD | 317.7万 USD | 300.8万 USD | 289.6万 USD | 306.8万 USD |
| 营业利润 | −2.87亿 USD | −1.95亿 USD | −1.55亿 USD | −1.15亿 USD | −7124.3万 USD |
| 净利润 | −2.59亿 USD | −1.58亿 USD | −1.41亿 USD | −1.12亿 USD | −7051.1万 USD |
公司数据更新于 2026年11月22日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$66.80
上涨空间 143.62%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2019年2月11日 | 1:15 | — | — |
股票拆分 | 2008年3月10日 | 1:12 | — | — |
已生效 2019年2月11日
1:15
已生效 2008年3月10日
1:12
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI5929.53万0.00%6893亿 USD0.03%US$340.02-3.52%
iShares Russell 2000 ETFIWM5744.24万0.08%715.37亿 USD0.19%US$256.61-2.88%
State Street SPDR S&P Biotech ETFXBI4594.51万0.48%96.36亿 USD0.35%US$140.18-2.73%
Vanguard Extended Market ETFVXF2696.44万0.03%302亿 USD0.05%US$211.44-3.21%
iShares Russell 2000 Growth ETFIWO1664.01万0.13%127.32亿 USD0.24%US$320.43-3.57%
Vanguard Russell 2000 ETFVTWO1383.28万0.08%168亿 USD0.06%US$103.76-2.76%
Dimensional - US Small Cap ETFDFAS1286.14万0.04%312.35亿 USD0.30%US$74.24-2.48%
Schwab U.S. Small-Cap ETFSCHA1143.31万0.06%204.47亿 USD0.03%US$30.51-2.83%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
State Street SPDR S&P Biotech ETFXBI
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Dimensional - US Small Cap ETFDFAS
Schwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。